메뉴 건너뛰기




Volumn 26, Issue 28, 2008, Pages 4532-4534

New lessons from "old" chemotherapy in colorectal cancer

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

EID: 53749097002     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.8145     Document Type: Editorial
Times cited : (2)

References (14)
  • 1
    • 84855806726 scopus 로고    scopus 로고
    • Colon cancer
    • NCCN: Clinical practice guidelines in oncology: Colon cancer. http:// www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree
    • Clinical practice guidelines in oncology
  • 2
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 3
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3
  • 4
    • 36048960109 scopus 로고    scopus 로고
    • Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study
    • Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 4779-4786
    • Fuchs, C.S.1    Marshall, J.2    Mitchell, E.3
  • 5
    • 42949150908 scopus 로고    scopus 로고
    • Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    • Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2006-2012
    • Cassidy, J.1    Clarke, S.2    Diaz-Rubio, E.3
  • 6
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3
  • 7
    • 53749092781 scopus 로고    scopus 로고
    • Oxaliplatin plus irinotecan compared to irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma
    • Haller D, Rothenberg M, Wong A, et al: Oxaliplatin plus irinotecan compared to irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26:4544-4550, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 4544-4550
    • Haller, D.1    Rothenberg, M.2    Wong, A.3
  • 8
    • 0037531121 scopus 로고    scopus 로고
    • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
    • Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
    • (2003) J Clin Oncol , vol.21 , pp. 2059-2069
    • Rothenberg, M.L.1    Oza, A.M.2    Bigelow, R.H.3
  • 9
    • 33646580151 scopus 로고    scopus 로고
    • N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU
    • suppl; abstr 3506, 247s
    • Pitot HC, Rowland KM, Sargent DJ, et al: N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. J Clin Oncol 23:247s, 2005 (suppl; abstr 3506)
    • (2005) J Clin Oncol , vol.23
    • Pitot, H.C.1    Rowland, K.M.2    Sargent, D.J.3
  • 10
    • 34447255724 scopus 로고    scopus 로고
    • Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial
    • Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370:143-152, 2007
    • (2007) Lancet , vol.370 , pp. 143-152
    • Seymour, M.T.1    Maughan, T.S.2    Ledermann, J.A.3
  • 11
    • 34547097252 scopus 로고    scopus 로고
    • Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    • Ashley AC, Sargent DJ, Alberts SR, et al: Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): Intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110:670-677, 2007
    • (2007) Cancer , vol.110 , pp. 670-677
    • Ashley, A.C.1    Sargent, D.J.2    Alberts, S.R.3
  • 12
    • 53749096264 scopus 로고    scopus 로고
    • Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials
    • suppl; abstr 4008, 180s
    • Sargent DJ, Marsoni S, Thibodeau SN, et al: Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26:180s, 2008 (suppl; abstr 4008)
    • (2008) J Clin Oncol , vol.26
    • Sargent, D.J.1    Marsoni, S.2    Thibodeau, S.N.3
  • 13
    • 84871470012 scopus 로고    scopus 로고
    • Bertagnolli MM, Compton CC, Niedzwiecki D, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. ASCO Meeting Abstracts 24:541s, 2006 (suppl; abstr 10003)
    • Bertagnolli MM, Compton CC, Niedzwiecki D, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. ASCO Meeting Abstracts 24:541s, 2006 (suppl; abstr 10003)
  • 14
    • 53749099787 scopus 로고    scopus 로고
    • Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin
    • suppl; abstr 15017, 645s
    • Zaanan A, Cuilliere-Dartigues P, Parc Y, et al: Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin. J Clin Oncol 26:645s, 2008 (suppl; abstr 15017)
    • (2008) J Clin Oncol , vol.26
    • Zaanan, A.1    Cuilliere-Dartigues, P.2    Parc, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.